U.K. Government Conducting Whole-City Screenings of Asymptomatic and Pre-Symptomatic People In an Aggressive Effort to Slow Dangerous, Third Wave of COVID-19
UK Clinical Trial Data Reports the Innova Medical Rapid Antigen Test Screened Asymptomatic Individuals with 98.98 Percent Accuracy,
Pasadena, Calif. (November 11, 2020) – Innova Medical Group, Inc. (IMG) has partnered with the UK Government in its rollout of whole-city screening and testing, beginning in Liverpool, with its INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test Kits. Innova Medical’s lateral flow antigen test uses nasal and throat swab samples to screen for infection, with highly accurate results in as little as 15-minutes. This test can be easily and safely administered anywhere, on both asymptomatic and symptomatic people, without costly delays and the need for a full-scale laboratory. With its low cost per test, about the same as a coffee and biscuit, at-risk populations and many with inequitable access to healthcare, can achieve peace-of-mind with a negative result. U.K. Government data showed the IMG rapid SARS-CoV-2 antigen test screened asymptomatic individuals with 98.98 percent accuracy.
Dr. Susan Hopkins, Incident Director at Public Health England, said, “The tests we are using in Liverpool are accurate, especially in finding people who are infectious at that moment in time and so are more likely to pass it on to others. Part of the purpose of working with Liverpool to roll out whole city testing, is to better understand how these tests work in the field, improve understanding on why people get tested and the impact of this approach on reducing the transmission rate.”
Using the National Health Service (NHS COVID-19) app, people can book a test and later input their test results. Individuals taking part in the rollout of Operation Moonshot, will be notified of positive or negative results by text or email. With this important test-and-trace system in place, public health authorities can diagnose cases, isolate infected patients, trace their contacts and implement stringent infection control policies to reduce outbreaks.
With colder months and the holiday season ahead, the risk of virus transmission accelerates with more indoor gatherings and travel. If people do not know they have COVID-19, it is unlikely they will take precautions to prevent virus spread. Research studies show that to achieve disease control both asymptomatic, people who are infected but never develop symptoms, and pre-symptomatic, infected people who develop symptoms later, must be isolated.
Under Operation Moonshot, the UK Government hopes to flatten the curve by employing proactive, rather than reactive, measures in its COVID-19 response. Up to 1-in-5 coronavirus infections present with no symptoms, but they are still contagious. The Centers for Disease Control and Prevention (CDC) says up to 40 percent of infected people are asymptomatic and should be tested if they have been exposed. Typically, a person develops symptoms 5 days after being infected; however, infectivity was found to be highest a day before symptom onset. After symptoms, such as a cough, fever, and shortness of breath, first appear, a person can remain contagious for at least ten days.
The Innova Rapid Antigen Test quickly identifies infectiousness. The lateral flow test can identify people with a high viral load who are the most likely to spread the virus. Daniel Elliott, President of Innova Medical Group, Inc., says “Our lateral flow device incorporates a German nitrocellulose membrane partially composed of nano particles of colloidal gold. This advanced, proprietary technology combined with our room temperature reagent, allows testing at point-of-care settings such as workplaces, universities, and airports.”
Innova Medical Group Inc. offers a global supply chain including the innovative and respected firms, GE Healthcare (USA) and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. By the end of November, IMG will produce millions of kits per day in its Brea, California plant, combined with activity from plants in other global locations. After being selected over a large number of submissions to take part in Operation Moonshot, IMG is also exploring options for production in the United Kingdom.
The Innova test carries a CE Marking indicating that this IVD device complies with the European In-Vitro Diagnostic Devices Directive (98/79/EC). This device may be legally commercialized in the European Union (EU).
Media Inquiries: firstname.lastname@example.org or +1 (626) 239 0025
About Innova Medical Group
Innova Medical Group, Inc. (IMG), is a wholly-owned subsidiary of Pasaca Capital (Pasadena, Calif.). IMG strategically pivoted and leveraged their expertise in Healthcare and Medical Devices to create an ecosystem to respond to the COVID-19 pandemic. The Innova Medical Ecosystem is delivering millions of tests every day to satisfy the diverse, point-of-care requirements of the world’s governments, large corporation, and institutions. IMG offers a global supply chain including the innovative and respected firms, GE Healthcare (USA) and Sartorius (Germany). IMG secured exclusive manufacturing and distribution agreements for its best-in-class portfolio of screening and diagnostic tests. For more information, visit www.innovamedgroup.com.